proxyvotesnow.com

Home › Companies › OCULAR THERAPEUTIX INC. › 2023-2024

OCULAR THERAPEUTIX INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and OCULAR THERAPEUTIX INC.’s Form 8-K, filed 2024-06-14 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 6Ballot items
  • 139Asset managers
  • 843Fund votes
  • 2024-06-12Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore OCULAR THERAPEUTIX INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by OCULAR THERAPEUTIX INC.

These tallies are OCULAR THERAPEUTIX INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-14 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

OCULAR THERAPEUTIX INC. — official shareholder meeting results, meeting held 2024-06-12
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Adrienne L. Graves, Ph.D. 85,368,917---- 389,15535,036,868 Majority: yes
Elect Director: Charles Warden 78,505,842---- 7,252,23035,036,868 Majority: yes
(2) The Company's stockholders approved a non-binding, advisory proposal regarding the compensation of the Company's named executive officers. 76,321,5099,265,164171,399 --35,036,868 Majority: yes
(3) The Company's stockholders approved Amendment No. 3 to increase the number of shares of common stock of the Company issuable under the 2021 Stock Incentive Plan by 7,000,000 shares. 84,021,2771,650,94785,848 --35,036,868 Majority: yes
(4) The Company's stockholders approved the proposal to amend the Company's Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 200,000,000 to 400,000,000. 112,604,8138,024,680165,447 ---- Majority: yes
(5) The Company's stockholders ratified the selection of PricewaterhouseCoopers LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2024. 119,634,478859,430301,032 ---- Majority: yes

Source: OCULAR THERAPEUTIX INC., Form 8-K, filed with the SEC on 2024-06-14 — read the filing on EDGAR.

How asset managers voted at the OCULAR THERAPEUTIX INC. 2023-2024 meeting

Each item below shows how the 139 asset managers that disclosed a OCULAR THERAPEUTIX INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. To approve an advisory vote on named executive officer compensation.

COMPENSATIONMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%11%
FOR: 76,321,509AGAINST: 9,265,164

OCULAR THERAPEUTIX INC.’s own tally for this item (“(2) The Company's stockholders approved a non-binding, advisory proposal regarding the compensation of the Company's named executive officers.”): 76,321,509 for, 9,265,164 against, per its Form 8-K filed 2024-06-14 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 154,704,086 outstanding shares: 49.3% for, 6% against (55% of the company cast a for/against vote).

The 137 asset managers below cast 88% of the shares they voted on this item FOR (62,096,282 for, 8,785,039 against).

FOR 88%12%
FOR: 62,096,282 (87.6%)AGAINST: 8,785,039 (12.4%)
Largest asset managers voting on “To approve an advisory vote on named executive officer compensation.” at OCULAR THERAPEUTIX INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Deep Track Capital, LP9,230,7690 00For
VR Adviser, LLC7,775,7600 00For
Vanguard7,259,8230 00For
Avoro Capital Advisors LLC7,148,9360 00For
Logos Global Management LP03,768,953 00Against
Citadel3,187,5010 00For
BlackRock2,594,9659,118 00For
DELTEC ASSET MANAGEMENT LLC2,295,3330 00For
GEODE CAPITAL MANAGEMENT, LLC2,273,3740 00For
Fidelity2,257,4680 00For
FRANKLIN ADVISERS INC02,168,284 00Against
State Street1,849,8474,381 00For
Octagon Capital Advisors LP1,839,6320 00For
T. Rowe Price1,742,9690 00For
GREAT POINT PARTNERS LLC1,728,7230 00For
PERCEPTIVE ADVISORS LLC1,394,4060 00For
ACUTA CAPITAL PARTNERS, LLC1,322,8780 00For
Invesco01,064,691 00Against
Nuveen832,7800 00For
TIAA824,6200 00For
Artia Global Partners LP775,8850 00For
FRANKLIN STRATEGIC SERIES0750,100 00Against
Point72704,7670 00For
Opaleye Management Inc.698,1380 00For
Northern Trust654,702530 00For

Showing the 25 largest of 137 asset managers. See all 137 in the interactive database.

2. To elect two Class I directors, each to serve until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Adrienne L. Graves, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99.5% Majority: yes · of votes cast

FOR 99.5%
FOR: 85,368,917WITHHELD: 389,155

OCULAR THERAPEUTIX INC.’s own tally for this item (“Elect Director: Adrienne L. Graves, Ph.D.”): 85,368,917 for, 389,155 withheld, per its Form 8-K filed 2024-06-14 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 154,704,086 outstanding shares: 55% for, 0.3% withheld (55% of the company cast a for/withheld vote).

The 39 asset managers below cast 100% of the shares they voted on this item FOR (14,390,145 for, 0 against).

FOR 100%
FOR: 14,390,145 (100.0%)
Largest asset managers voting on “To elect two Class I directors, each to serve until the 2027 Annual Meeting of Stockholders and until his or h” at OCULAR THERAPEUTIX INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard7,022,8090 00For
Fidelity2,186,7300 00For
TIAA824,6200 00For
T. Rowe Price774,8750 00For
FRANKLIN STRATEGIC SERIES750,1000 00For
Invesco519,1670 00For
BlackRock505,7530 00For
Charles Schwab316,4710 00For
Equitable311,4960 00For
QUANTITATIVE MASTER SERIES LLC176,9120 00For
State Street157,2120 00For
PARADIGM FUNDS140,0000 00For
Lincoln Financial92,9000 00For
1290 Funds80,1110 00For
John Hancock66,7030 00For
AIG/SunAmerica56,9810 00For
Goldman Sachs48,6930 00For
Pacific Life38,6850 00For
Voya36,9560 00For
Global X36,1970 00For
Brighthouse34,2960 00For
ProShares34,0270 00For
Nationwide31,3950 00For
Bridge Builder Trust21,6190 00For
SEI18,4000 00For

Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.

3. To elect two Class I directors, each to serve until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Charles Warden

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%8%
FOR: 78,505,842WITHHELD: 7,252,230

OCULAR THERAPEUTIX INC.’s own tally for this item (“Elect Director: Charles Warden”): 78,505,842 for, 7,252,230 withheld, per its Form 8-K filed 2024-06-14 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 154,704,086 outstanding shares: 50.7% for, 5% withheld (55% of the company cast a for/withheld vote).

The 39 asset managers below cast 100% of the shares they voted on this item FOR (13,479,517 for, 0 against).

FOR 94%
FOR: 13,479,517 (93.7%)ABSTAIN: 910,628 (6.3%)
Largest asset managers voting on “To elect two Class I directors, each to serve until the 2027 Annual Meeting of Stockholders and until his or h” at OCULAR THERAPEUTIX INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard7,022,8090 00For
Fidelity2,186,7300 00For
TIAA824,6200 00For
T. Rowe Price774,8750 00For
FRANKLIN STRATEGIC SERIES00 750,1000Abstain
Invesco519,1670 00For
BlackRock505,7530 00For
Charles Schwab316,4710 00For
Equitable206,5460 104,9500For
QUANTITATIVE MASTER SERIES LLC176,9120 00For
State Street157,1900 220For
PARADIGM FUNDS140,0000 00For
Lincoln Financial92,9000 00For
1290 Funds80,1110 00For
John Hancock66,7030 00For
AIG/SunAmerica56,9810 00For
Goldman Sachs48,6930 00For
Pacific Life38,6850 00For
Voya36,9560 00For
Global X00 36,1970Abstain
Brighthouse34,2960 00For
ProShares34,0270 00For
Nationwide30,4360 9590For
Bridge Builder Trust21,6190 00For
SEI00 18,4000Abstain

Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.

4. To approve an amendment to the Ocular Therapeutix, Inc. 2021 Stock Incentive Plan, as amended, to increase the number of shares of common stock issuable thereunder by 7,000,000 shares.

COMPENSATIONMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 84,021,277AGAINST: 1,650,947

OCULAR THERAPEUTIX INC.’s own tally for this item (“(3) The Company's stockholders approved Amendment No. 3 to increase the number of shares of common stock of the Company issuable under the 2021 Stock Incentive Plan by 7,000,000 shares.”): 84,021,277 for, 1,650,947 against, per its Form 8-K filed 2024-06-14 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 154,704,086 outstanding shares: 54.3% for, 1% against (55% of the company cast a for/against vote).

The 39 asset managers below cast 99.9% of the shares they voted on this item FOR (14,378,592 for, 11,553 against).

FOR 99.9%
FOR: 14,378,592 (99.9%)AGAINST: 11,553 (0.1%)
Largest asset managers voting on “To approve an amendment to the Ocular Therapeutix, Inc. 2021 Stock Incentive Plan, as amended, to increase the” at OCULAR THERAPEUTIX INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard7,022,8090 00For
Fidelity2,186,7300 00For
TIAA824,6200 00For
T. Rowe Price774,8750 00For
FRANKLIN STRATEGIC SERIES750,1000 00For
Invesco519,1670 00For
BlackRock505,7530 00For
Charles Schwab316,4710 00For
Equitable311,4960 00For
QUANTITATIVE MASTER SERIES LLC176,9120 00For
State Street157,19022 00For
PARADIGM FUNDS140,0000 00For
Lincoln Financial92,9000 00For
1290 Funds80,1110 00For
John Hancock66,7030 00For
AIG/SunAmerica56,9810 00For
Goldman Sachs48,6930 00For
Pacific Life38,6850 00For
Voya36,9560 00For
Global X36,1970 00For
Brighthouse34,2960 00For
ProShares34,0270 00For
Nationwide31,3950 00For
Bridge Builder Trust21,6190 00For
SEI18,4000 00For

Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.

5. To approve an amendment to our Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of our common stock from 200,000,000 shares to 400,000,000 shares.

CAPITAL STRUCTUREMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%
FOR: 112,604,813AGAINST: 8,024,680

OCULAR THERAPEUTIX INC.’s own tally for this item (“(4) The Company's stockholders approved the proposal to amend the Company's Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 200,000,000 to 400,000,000.”): 112,604,813 for, 8,024,680 against, per its Form 8-K filed 2024-06-14 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 154,704,086 outstanding shares: 73% for, 5% against (78% of the company cast a for/against vote).

The 39 asset managers below cast 99.9% of the shares they voted on this item FOR (14,390,132 for, 13 against).

FOR 99.9%
FOR: 14,390,132 (100.0%)AGAINST: 13 (0.0%)
Largest asset managers voting on “To approve an amendment to our Restated Certificate of Incorporation, as amended, to increase the number of au” at OCULAR THERAPEUTIX INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard7,022,8090 00For
Fidelity2,186,7300 00For
TIAA824,6200 00For
T. Rowe Price774,8750 00For
FRANKLIN STRATEGIC SERIES750,1000 00For
Invesco519,1670 00For
BlackRock505,7530 00For
Charles Schwab316,4710 00For
Equitable311,4960 00For
QUANTITATIVE MASTER SERIES LLC176,9120 00For
State Street157,19913 00For
PARADIGM FUNDS140,0000 00For
Lincoln Financial92,9000 00For
1290 Funds80,1110 00For
John Hancock66,7030 00For
AIG/SunAmerica56,9810 00For
Goldman Sachs48,6930 00For
Pacific Life38,6850 00For
Voya36,9560 00For
Global X36,1970 00For
Brighthouse34,2960 00For
ProShares34,0270 00For
Nationwide31,3950 00For
Bridge Builder Trust21,6190 00For
SEI18,4000 00For

Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.

6. To ratify the appointment of PricewaterhouseCoopers LLP as Ocular Therapeutix's independent registered public accounting firm for the fiscal year ending December 31, 2024.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99.2% Majority: yes · of votes cast

FOR 99.2%
FOR: 119,634,478AGAINST: 859,430

OCULAR THERAPEUTIX INC.’s own tally for this item (“(5) The Company's stockholders ratified the selection of PricewaterhouseCoopers LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2024.”): 119,634,478 for, 859,430 against, per its Form 8-K filed 2024-06-14 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 154,704,086 outstanding shares: 77% for, 0.6% against (78% of the company cast a for/against vote).

The 39 asset managers below cast 99.9% of the shares they voted on this item FOR (14,390,123 for, 22 against).

FOR 99.9%
FOR: 14,390,123 (100.0%)AGAINST: 22 (0.0%)
Largest asset managers voting on “To ratify the appointment of PricewaterhouseCoopers LLP as Ocular Therapeutix's independent registered public ” at OCULAR THERAPEUTIX INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard7,022,8090 00For
Fidelity2,186,7300 00For
TIAA824,6200 00For
T. Rowe Price774,8750 00For
FRANKLIN STRATEGIC SERIES750,1000 00For
Invesco519,1670 00For
BlackRock505,7530 00For
Charles Schwab316,4710 00For
Equitable311,4960 00For
QUANTITATIVE MASTER SERIES LLC176,9120 00For
State Street157,19022 00For
PARADIGM FUNDS140,0000 00For
Lincoln Financial92,9000 00For
1290 Funds80,1110 00For
John Hancock66,7030 00For
AIG/SunAmerica56,9810 00For
Goldman Sachs48,6930 00For
Pacific Life38,6850 00For
Voya36,9560 00For
Global X36,1970 00For
Brighthouse34,2960 00For
ProShares34,0270 00For
Nationwide31,3950 00For
Bridge Builder Trust21,6190 00For
SEI18,4000 00For

Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.

Largest OCULAR THERAPEUTIX INC. shareholders voting in 2023-2024

Ranked by the number of OCULAR THERAPEUTIX INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 154,704,086 shares outstanding at the time of that meeting.

Top OCULAR THERAPEUTIX INC. shareholders by shares voted, 2023-2024
#Asset manager % of shares outstanding
1Deep Track Capital, LP 5.97%
2VR Adviser, LLC 5.03%
3Vanguard 4.69%
4Avoro Capital Advisors LLC 4.62%
5Logos Global Management LP 2.44%
6Citadel 2.06%
7BlackRock 1.68%
8DELTEC ASSET MANAGEMENT LLC 1.48%
9GEODE CAPITAL MANAGEMENT, LLC 1.47%
10Fidelity 1.46%

Reported OCULAR THERAPEUTIX INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

OCULAR THERAPEUTIX INC. beneficial owners on record for the 2023-2024 proxy season
Holder % outstanding Disclosure
FMR (Fidelity) 20.55% 13F
BlackRock 6.82% 13F
Vanguard Group 5.92% 13F
Citadel Advisors 3.64% 13F
Geode Capital 1.61% 13F
Morgan Stanley 1.59% 13F
State Street 1.55% 13F
Franklin Templeton 1.40% 13F
Nuveen 0.78% 13F
Northern Trust 0.63% 13F

Percentages above are of 154,704,086 shares outstanding, as reported by OCULAR THERAPEUTIX INC. on its Form 10-Q dated 2024-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from OCULAR THERAPEUTIX INC.’s 10-Q dated 2024-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At OCULAR THERAPEUTIX INC.'s shareholder meeting held 2024-06-12, in the 2023-2024 proxy season, 139 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 843 separate fund positions. On the most widely held item on that ballot — To approve an advisory vote on named executive officer compensation. — FOR was 89% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: OCULAR THERAPEUTIX INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-06-14.

OCULAR THERAPEUTIX INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.